Alex Godwood
Cambridge, ENG CB216DG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.
Journal: Nature medicine
Published: April 14, 2025
A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas.
Journal: European journal of endocrinology
Published: September 07, 2023
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease.
Journal: Clinical pharmacology and therapeutics
Published: August 15, 2023
Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
Journal: International journal of rheumatic diseases
Published: March 26, 2018
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 03, 2017
Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
Journal: Rheumatology (Oxford, England)
Published: April 13, 2017
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 05, 2017
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Journal: Annals of the rheumatic diseases
Published: September 30, 2016
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.
Journal: Annals of the rheumatic diseases
Published: December 14, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026